# KIORA PHARMACEUTICALS INC (KPRX) — merger/scheme_of_arrangement [completed]
Source: sec.gov · situation sit_abdcd8b43f2b1eb332d2 · public 4266547202145603888 · retrieved 2026-08-21T14:15:13.341Z

## Overview
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease, including KIO-301, a molecular photoswitch designed to restore light sensitivity in degenerated retinal cells for inherited retinal diseases such as retinitis pigmentosa.

Kiora Pharmaceuticals granted Chong Kun Dang Pharmaceutical Corporation (CKD) an exclusive license to develop, manufacture, commercialize, and seek regulatory approvals for KIO-301 (a molecular photoswitch) in South Korea for ophthalmology indications, effective August 20, 2026. CKD will pay Kiora a $1.0 million upfront fee and is eligible to receive development, regulatory, and sales milestone payments. Kiora is also eligible to receive double-digit royalties on net sales of KIO-301 in South Korea. The parties anticipate coordinating a single global Phase 3 clinical trial for KIO-301 in retinitis pigmentosa with Kiora's other development and commercialization partners.

## Terms
- Counterparty: Chong Kun Dang Pharmaceutical Corporation · Deal value: $1.0M · Consideration: mixed

## Key dates
- Completed 2026-08-20

## Timeline
- 2026-08-19 · 8-K (0001372514-26-000077): 8-K - KIORA PHARMACEUTICALS INC — *Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease, including KIO-301, a molecular photoswitch designed to restore light sensitivity in degenerated retinal cells for inherited retinal diseases such as retinitis pigmentosa.* Kiora Pharmaceuticals granted Chong Kun Dang Pharmaceutical Corporation (CKD) an exclusive license to develop, manufacture, commercialize, and seek regulatory approvals for KIO-301 (a molecular photoswitch) in South Korea for ophthalmology indications, effective August 20, 2026. CKD will pay Kiora a $1.0 million upfront fee and is eligible to receive development, regulatory, and sales milestone payments. Kiora is also eligible to receive double-digit royalties on net sales of KIO-301 in South Korea. The parties anticipate coordinating a single global Phase 3 clinical trial for KIO-301 in retinitis pigmentosa with Kiora's other development and commercialization partners.
  https://www.sec.gov/Archives/edgar/data/1372514/0001372514-26-000077.txt

## Citations
- 0001372514-26-000077 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000137251426000077